Praxis Precision Medicines (PRAX) closed at $324.76 on November 12, 2026, down 6.2% from the previous close, on volume of 562,376 shares (30-day average 494,381).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 22, 2026 | Condor With Puts | 21-Jan-28190 : 200 : 210 : 220 P | 2,000 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
Praxis Precision Medicines Outlines Commercial Strategy at Investor Day
TipRanks (Thu, 12-Nov 6:04 PM ET)
Globe Newswire (Thu, 12-Nov 4:30 PM ET)
Praxis Precision Medicines: Late-Stage Pipeline and Regulatory Catalysts Support Buy Rating
TipRanks (Tue, 10-Nov 10:55 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Tue, 10-Nov 8:40 AM ET)
Oppenheimer Sticks to Its Buy Rating for Praxis Precision Medicines (PRAX)
TipRanks (Tue, 10-Nov 7:55 AM ET)
Praxis Precision Medicines (PRAX) Gets a Buy from RBC Capital
TipRanks (Tue, 10-Nov 6:55 AM ET)
Buy Rating Reaffirmed with Unchanged $1,201 Price Target Ahead of Key FDA Decisions
TipRanks (Tue, 10-Nov 6:45 AM ET)
Praxis Precision Medicines (PRAX) Gets a Buy from BTIG
TipRanks (Tue, 10-Nov 6:16 AM ET)
TipRanks (Tue, 10-Nov 5:50 AM ET)
Piper Sandler Remains a Buy on Praxis Precision Medicines (PRAX)
TipRanks (Mon, 9-Nov 9:25 AM ET)
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Praxis Precision Medicines trades on the NASDAQ stock market under the symbol PRAX.
As of November 12, 2026, PRAX stock price declined to $324.76 with 562,376 million shares trading.
PRAX has a beta of 1.88, meaning it tends to be more sensitive to market movements. PRAX has a correlation of 0.13 to the broad based SPY ETF.
PRAX has a market cap of $9.08 billion. This is considered a Mid Cap stock.
Last quarter Praxis Precision Medicines reported $0 in Revenue and -$3.23 earnings per share. This fell short of revenue expectation by $-485,000 and exceeded earnings estimates by $.41.
In the last 3 years, PRAX traded as high as $392.70 and as low as $13.01.
The top ETF exchange traded funds that PRAX belongs to (by Net Assets): VTI, IWM, VB, XBI, VBR.
PRAX has outperformed the market in the last year with a price return of +76.9% while the SPY ETF gained +12.0%. However, in the short term, PRAX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -12.4% vs -1.5% return in SPY. But in the last 2 weeks, PRAX shares have fared better than the market returning +13.8% compared to SPY -2.0%.
PRAX support price is $333.51 and resistance is $358.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRAX shares will trade within this expected range on the day.
